|
1
|
Martin HL, Smith L and Tomlinson DC:
Multidrug-resistant breast cancer: Current perspectives. Breast
Cancer. 6:1–13. 2014.PubMed/NCBI
|
|
2
|
Gong J, Jaiswal R, Mathys JM, Combes V,
Grau GE and Bebawy M: Microparticles and their emerging role in
cancer multidrug resistance. Cancer Treat Rev. 38:226–234. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Abbas T and Dutta A: p21 in cancer:
Intricate networks and multiple activities. Nat Rev Cancer.
9:400–414. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Achuthan S, Santhoshkumar TR, Prabhakar J,
Nair SA and Pillai MR: Drug-induced senescence generates
chemoresistant stemlike cells with low reactive oxygen species. J
Biol Chem. 286:37813–37829. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hawthorne VS, Huang WC, Neal CL, Tseng LM,
Hung MC and Yu D: ErbB2-mediated Src and signal transducer and
activator of transcription 3 activation leads to transcriptional
up-regulation of p21Cip1 and chemoresistance in breast
cancer cells. Mol Cancer Res. 7:592–600. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vasiliou V, Vasiliou K and Nebert DW:
Human ATP-binding cassette (ABC) transporter family. Hum Genomics.
3:281–290. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liang Y, Li S and Chen L: The
physiological role of drug transporters. Protein Cell. 6:334–350.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Abdullah LN and Chow EK: Mechanisms of
chemoresistance in cancer stem cells. Clin Transl Med. 2:3–12.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Meyer MJ, Fleming JM, Lin AF, Hussnain SA,
Ginsburg E and Vonderhaar BK:
CD44posCD49fhiCD133/2hi defines
xenograft-initiating cells in estrogen receptor-negative breast
cancer. Cancer Res. 70:4624–4633. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bhat-Nakshatri P, Goswami CP, Badve S,
Sledge GW Jr and Nakshatri H: Identification of FDA-approved drugs
targeting breast cancer stem cells along with biomarkers of
sensitivity. Sci Rep. 3:2530–2542. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
May CD, Sphyris N, Evans KW, Werden SJ,
Guo W and Mani SA: Epithelial-mesenchymal transition and cancer
stem cells: A dangerously dynamic duo in breast cancer progression.
Breast Cancer Res. 13:202–212. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sarrio D, Franklin CK, Mackay A,
Reis-Filho JS and Isacke CM: Epithelial and mesenchymal
subpopulations within normal basal breast cell lines exhibit
distinct stem cell/progenitor properties. Stem Cells. 30:292–303.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shrivastava A, Tiwari M, Sinha RA, Kumar
A, Balapure AK, Bajpai VK, Sharma R, Mitra K, Tandon A and Godbole
MM: Molecular iodine induces caspase-independent apoptosis in human
breast carcinoma cells involving the mitochondria-mediated pathway.
J Biol Chem. 281:19762–19771. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nuñez-Anita RE, Arroyo-Helguera O,
Cajero-Juárez M, López-Bojorquez L and Aceves C: A complex between
6-iodolactone and the peroxisome proliferator-activated receptor
type gamma may mediate the antineoplastic effect of iodine in
mammary cancer. Prostaglandins Other Lipid Mediat. 89:34–42. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nava-Villalba M, Nuñez-Anita RE, Bontempo
A and Aceves C: Activation of peroxisome proliferator-activated
receptor gamma is crucial for antitumoral effects of 6-iodolactone.
Mol Cancer. 14:168–173. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Alfaro Y, Delgado G, Cárabez A, Anguiano B
and Aceves C: Iodine and doxorubicin, a good combination for
mammary cancer treatment: Antineoplastic adjuvancy, chemoresistance
inhibition, and cardioprotection. Mol Cancer. 12:45–55. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Peralta G, Torres JM, Delgado G, Dominguez
A, De Obaldía R, Duarte L, Paredes E, Avecilla C, Hernández S,
Vega-Riverol L, et al: Iodine exhibits dual effects on breast
cancer as a co-treatment with anthracyclines: Anti-neoplastic
synergy and cardioprotector. In 102nd Annual Meeting, AACR,
Orlando, FL, 2011. (adstract 3509). Cancer Res. 71(Suppl 8): pp.
35092011; doi: 10.1158/1538-7445.AM2011-3509.
|
|
18
|
Gong JH, Liu XJ, Shang BY, Chen SZ and
Zhen YS: HERG K+ channel related chemosensitivity to
sparfloxacin in colon cancer cells. Oncol Rep. 23:1747–1756.
2010.PubMed/NCBI
|
|
19
|
Thompson HJ: Methods for the induction of
mammary carcinogenesis in the rat using either
7,12-dimethylbenz[a]antracene or 1-methyl-1-nitrosoureaMethods in
Mammary Gland Biology and Breast Cancer Research. Ip M and Aschz
BB: 8th edition. Kluwer Academic/Plenum Publishers; NY: pp. 19–29.
2000, View Article : Google Scholar
|
|
20
|
Mehta K, Devarajan E, Chen J, Multani A
and Pathak S: Multidrug-resistant MCF-7 cells: An identity crisis?
J Natl Cancer Inst. 94:1652–1654. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pirnia F, Breuleux M, Schneider E,
Hochmeister M, Bates SE, Marti A, Hotz MA, Betticher DC and Borner
MM: Uncertain identity of doxorubicin-resistant MCF-7 cell lines
expressing mutated p53. J Natl Cancer Inst. 92:1535–1536. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Calcagno AM, Fostel JM, To KKW, Salcido
CD, Martin SE, Chewning KJ, Wu CP, Varticovski L, Bates SE, Caplen
NJ, et al: Single-step doxorubicin-selected cancer cells
overexpress the ABCG2 drug transporter through epigenetic changes.
Br J Cancer. 98:1515–1524. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kars MD, Iseri OD, Gündüz U, Ural AU,
Arpaci F and Molnár J: Development of rational in vitro models for
drug resistance in breast cancer and modulation of MDR by selected
compounds. Anticancer Res. 26:4559–4568. 2006.PubMed/NCBI
|
|
24
|
Mehta K: High levels of transglutaminase
expression in doxorubicin-resistant human breast carcinoma cells.
Int J Cancer. 58:400–406. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Calcagno AM, Salcido CD, Gillet JP, Wu CP,
Fostel JM, Mumau MD, Gottesman MM, Varticovski L and Ambudkar SV:
Prolonged drug selection of breast cancer cells and enrichment of
cancer stem cell characteristics. J Natl Cancer Inst.
102:1637–1652. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Järvinen TA, Tanner M, Rantanen V, Bärlund
M, Borg A, Grénman S and Isola J: Amplification and deletion of
topoisomerase IIalpha associate with ErbB-2 amplification and
affect sensitivity to topoisomerase II inhibitor doxorubicin in
breast cancer. Am J Pathol. 156:839–847. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
AbuHammad S and Zihlif M: Gene expression
alterations in doxorubicin resistant MCF7 breast cancer cell line.
Genomics. 101:213–220. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Arroyo-Helguera O, Rojas E, Delgado G and
Aceves C: Signaling pathways involved in the antiproliferative
effect of molecular iodine in normal and tumoral breast cells:
Evidence that 6-iodolactone mediates apoptotic effects. Endocr
Relat Cancer. 15:1003–1011. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rösner H, Torremante P, Möller W and
Gärtner R: Antiproliferative/cytotoxic activity of molecular iodine
and iodolactones in various human carcinoma cell lines. No
interfering with EGF-signaling, but evidence for apoptosis. Exp
Clin Endocrinol Diabetes. 118:410–419. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Smart CE, Morrison BJ, Saunus JM, Vargas
AC, Keith P, Reid L, Wockner L, Askarian-Amiri M, Sarkar D, Simpson
PT, et al: In vitro analysis of breast cancer cell line
tumourspheres and primary human breast epithelia mammospheres
demonstrates inter- and intrasphere heterogeneity. PLoS One.
8:e643882013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang H, Jing X, Wu X, Hu J, Zhang X, Wang
X, Su P, Li W and Zhou G: Suppression of multidrug resistance by
rosiglitazone treatment in human ovarian cancer cells through
downregulation of FZD1 and MDR1 genes. Anticancer Drugs.
26:706–715. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Weiss J, Sauer A, Herzog M, Böger RH,
Haefeli WE and Benndorf RA: Interaction of thiazolidinediones
(glitazones) with the ATP-binding cassette transporters
P-glycoprotein and breast cancer resistance protein. Pharmacology.
84:264–270. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
van Herwaarden AE, Wagenaar E, Merino G,
Jonker JW, Rosing H, Beijnen JH and Schinkel AH: Multidrug
transporter ABCG2/breast cancer resistance protein secretes
riboflavin (vitamin B2) into milk. Mol Cell Biol.
27:1247–1253. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ruiz-Vela A, Aguilar-Gallardo C,
Martínez-Arroyo AM, Soriano-Navarro M, Ruiz V and Simón C: Specific
unsaturated fatty acids enforce the transdifferentiation of human
cancer cells toward adipocyte-like cells. Stem Cell Rev. 7:898–909.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Davies GF, Juurlink BH and Harkness TA:
Troglitazone reverses the multiple drug resistance phenotype in
cancer cells. Drug Des Devel Ther. 3:79–88. 2009.PubMed/NCBI
|
|
36
|
Aranda N, Sosa S, Delgado G, Aceves C and
Anguiano B: Uptake and antitumoral effects of iodine and
6-iodolactone in differentiated and undifferentiated human prostate
cancer cell lines. Prostate. 73:31–41. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Núñez-Anita RE, Nava-Villalba M and Aceves
C: Dose-dependent apoptotic effect of molecular iodine in two
neuroblastoma cell lines. Possible Participation of Retinoic Acid
Receptor. 14th International Thyroid Congress, Paris, France, Sept
2010. https://www.thyroid.org/professionals/meetings/past-meetings/14th-international-thyroid-congress/
|
|
38
|
Soave DF, da Costa JP Oliveira, da
Silveira GG, Ianez RC, de Oliveira LR, Lourenço SV and
Ribeiro-Silva A: CD44/CD24 immunophenotypes on clinicopathologic
features of salivary glands malignant neoplasms. Diagn Pathol.
8:29–40. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ohara Y, Oda T, Sugano M, Hashimoto S,
Enomoto T, Yamada K, Akashi Y, Miyamoto R, Kobayashi A, Fukunaga K,
et al: Histological and prognostic importance of
CD44+/CD24+/EpCAM+ expression in
clinical pancreatic cancer. Cancer Sci. 104:1127–1134. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yeung TM, Gandhi SC, Wilding JL, Muschel R
and Bodmer WF: Cancer stem cells from colorectal cancer-derived
cell lines. Proc Natl Acad Sci USA. 107:pp. 3722–3727. 2010;
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kristiansen G, Winzer KJ, Mayordomo E,
Bellach J, Schlüns K, Denkert C, Dahl E, Pilarsky C, Altevogt P,
Guski H, et al: CD24 expression is a new prognostic marker in
breast cancer. Clin Cancer Res. 9:4906–4913. 2003.PubMed/NCBI
|
|
42
|
Bretz N, Noske A, Keller S, Erbe-Hofmann
N, Schlange T, Salnikov AV, Moldenhauer G, Kristiansen G and
Altevogt P: CD24 promotes tumor cell invasion by suppressing tissue
factor pathway inhibitor-2 (TFPI-2) in a c-Src-dependent fashion.
Clin Exp Metastasis. 29:27–38. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ma ZL, Chen YP, Song JL and Wang YQ:
Knockdown of CD24 inhibits proliferation, invasion and sensitizes
breast cancer MCF-7 cells to tamoxifen in vitro. Eur Rev Med
Pharmacol Sci. 19:2394–2399. 2015.PubMed/NCBI
|
|
44
|
Mylona E, Giannopoulou I, Fasomytakis E,
Nomikos A, Magkou C, Bakarakos P and Nakopoulou L: The
clinicopathologic and prognostic significance of
CD44+/CD24−/low and CD44/CD24+
tumor cells in invasive breast carcinomas. Hum Pathol.
39:1096–1102. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Chen Y, Song J, Jiang Y, Yu C and Ma Z:
Predictive value of CD44 and CD24 for prognosis and chemotherapy
response in invasive breast ductal carcinoma. Int J Clin Exp
Pathol. 8:11287–11295. 2015.PubMed/NCBI
|
|
46
|
Shen YA, Wei YH and Chen YJ: High
CD44/CD24 expressive cells presented cancer stem cell
characteristics and undergo mitochondrial resetting and metabolic
shift in nasopharyngeal carcinoma. Cancer Res. 71 Suppl 8:Abstract
nr 4822011. View Article : Google Scholar
|
|
47
|
Onder TT, Gupta PB, Mani SA, Yang J,
Lander ES and Weinberg RA: Loss of E-cadherin promotes metastasis
via multiple downstream transcriptional pathways. Cancer Res.
68:3645–3654. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Satelli A and Li S: Vimentin in cancer and
its potential as a molecular target for cancer therapy. Cell Mol
Life Sci. 68:3033–3046. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Tan X, Dagher H, Hutton CA and Bourke JE:
Effects of PPARγ ligands on TGF-β1-induced epithelial-mesenchymal
transition in alveolar epithelial cells. Respir Res. 11:21–33.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Reka AK, Kurapati H, Narala VR, Bommer G,
Chen J, Standiford TJ and Keshamouni VG: Peroxisome
proliferator-activated receptor-γ activation inhibits tumor
metastasis by antagonizing Smad3-mediated epithelial-mesenchymal
transition. Mol Cancer Ther. 9:3221–3232. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Elrod HA and Sun SY: PPARgamma and
apoptosis in cancer. PPAR Res. 2008:7041652008. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Burstein HJ, Demetri GD, Mueller E, Sarraf
P, Spiegelman BM and Winer EP: Use of the peroxisome
proliferator-activated receptor (PPAR) gamma ligand troglitazone as
treatment for refractory breast cancer: A phase II study. Breast
Cancer Res Treat. 79:391–397. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Girnun GD, Chen L, Silvaggi J, Drapkin R,
Chirieac LR, Padera RF, Upadhyay R, Vafai SB, Weissleder R, Mahmood
U, et al: Regression of drug-resistant lung cancer by the
combination of rosiglitazone and carboplatin. Clin Cancer Res.
14:6478–6486. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Bräutigam K, Biernath-Wüpping J,
Bauerschlag DO, von Kaisenberg CS, Jonat W, Maass N, Arnold N and
Meinhold-Heerlein I: Combined treatment with TRAIL and PPARγ
ligands overcomes chemoresistance of ovarian cancer cell lines. J
Cancer Res Clin Oncol. 137:875–886. 2011. View Article : Google Scholar : PubMed/NCBI
|
